Please login to the form below

Not currently logged in
Email:
Password:

CDK4/6 inhibitor

This page shows the latest CDK4/6 inhibitor news and features for those working in and with pharma, biotech and healthcare.

NICE nod for Lilly’s breast cancer drug Verzenio via CDF

NICE nod for Lilly’s breast cancer drug Verzenio via CDF

Helps Lilly drug in pursuit of Ibrance and Kisqali. Thousands of women with advanced breast cancer could get access to treatment with Eli Lilly’s CDK 4/6 inhibitor Verzenio, after ... $6bn product at peak by EvaluatePharma – as well as Novartis’

Latest news

  • NICE gives Lilly’s Verzenios chance to compete with rivals NICE gives Lilly’s Verzenios chance to compete with rivals

    CDK4/6 inhibitor class. ... Around 46, 000 women are diagnosed with breast cancer each year in England and Wales, of whom around 8, 000 would be eligible for treatment with a CDK4/6 inhibitor.

  • CHMP backs Sanofi’s all-oral sleeping sickness drug CHMP backs Sanofi’s all-oral sleeping sickness drug

    Among these, Novartis’ CDK4/6 inhibitor Kisqali (ribociclib) was recommended for the treatment of women with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer in combination with fulvestrant

  • Novartis claims a rare win at ESMO for PI3K inhibitor class Novartis claims a rare win at ESMO for PI3K inhibitor class

    16%. Alpelisib was also fairly well tolerated in the 572-patient study, which involved patients whose disease had progressed after earlier treatment with an aromatase inhibitor with or without a ... 6 inhibitor, a newer drug group which includes

  • Lilly gets EMA nod for Verzenio in breast cancer Lilly gets EMA nod for Verzenio in breast cancer

    Eli Lilly has the approval it was looking for in Europe for CDK4/6 inhibitor Verzenio, allowing to challenge rivals from Pfizer and Novartis in breast cancer. ... women. It’s not all been plain sailing for Lilly’s CDK4/6 inhibitor programme however.

  • Novartis considers filings for PI3K drug in breast cancer Novartis considers filings for PI3K drug in breast cancer

    Novartis has positive phase III results in hand for its PI3K inhibitor alpelisib in advanced breast cancer patients, which it hopes will be enough to file for regulatory approvals. ... The two regimens were compared in patients whose cancer had

More from news
Approximately 2 fully matching, plus 22 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics